Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director · President and CEO | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,120,384 |
Reported balance
After 2026-08-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-12 · Gift · Disposed 32,220 · Balance 2,120,384 F1: Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund. F2: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | Direct | 296,833 |
Reported balance
Holding disclosure · report date 2026-08-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 296,833 F3: Includes 184,915 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund.
F2: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F3: Includes 184,915 unvested RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2022 Filed Feb 15, 2022 23:58 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,491 | $34.72 | $329,527.52 |
DisclosureSEC source: 0001714899-22-000042 · wf-form4_164496949316138.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,129,648 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $34.50 to $35.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 19,697 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 6,118 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0001714899-22-000035 · wf-form4_164461792855991.xml · derivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,118 shares Expires 2027-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option were fully vested and exercisable. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 64,631 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001714899-22-000035 · wf-form4_164461792855991.xml · derivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,631 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option were fully vested and exercisable. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 6,118 | $9.60 | $58,732.80 |
DisclosureSEC source: 0001714899-22-000035 · wf-form4_164461792855991.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 8800 restricted stock units held by the Reporting Person. F5 · balance_after: Includes 189,891 restricted stock units. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 64,631 | $5.28 | $341,251.68 |
DisclosureSEC source: 0001714899-22-000035 · wf-form4_164461792855991.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,719 | $37.55 | $102,103.62 |
DisclosureSEC source: 0001714899-22-000035 · wf-form4_164461792855991.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,119,442 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $37.51 to $37.745 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 8800 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 23:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,007 | $44.78 | $224,213.46 |
DisclosureSEC source: 0001714899-22-000008 · wf-form4_164159676820157.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,113,361 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.44 to $45.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 15000 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 186,500 | $0.00 Strike: $47.27 | $0.00 |
DisclosureSEC source: 0001714899-22-000002 · wf-form4_164142738905570.xml · derivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,500 Underlying: Common Stock · 186,500 shares Expires 2032-01-02 F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2023, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 62,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000002 · wf-form4_164142738905570.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,691 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2023 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 213,691 restricted stock units. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:23 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 805 | $46.35 | $37,311.75 |
DisclosureSEC source: 0001714899-21-000114 · wf-form4_163856660331306.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,103,368 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $45.99 to $46.71 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:23 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,012 | $45.30 | $408,243.60 |
DisclosureSEC source: 0001714899-21-000114 · wf-form4_163856660331306.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,104,173 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $44.96 to $45.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:23 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,516 | $44.39 | $378,025.24 |
DisclosureSEC source: 0001714899-21-000114 · wf-form4_163856660331306.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,113,185 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $43.96 to $44.935 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:32 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 16,674 | $49.87 | $831,532.38 |
DisclosureSEC source: 0001714899-21-000097 · wf-form4_163597513221470.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,121,701 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $49.27 to $50.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:32 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,659 | $48.61 | $80,643.99 |
DisclosureSEC source: 0001714899-21-000097 · wf-form4_163597513221470.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,138,375 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $48.20 to $49.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,247 | $50.99 | $216,554.53 |
DisclosureSEC source: 0001714899-21-000093 · wf-form4_163346563868452.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,140,034 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $50.90 to $51.14 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,782 | $50.44 | $543,844.08 |
DisclosureSEC source: 0001714899-21-000093 · wf-form4_163346563868452.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,144,281 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $49.90 to $50.895 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,304 | $49.38 | $163,151.52 |
DisclosureSEC source: 0001714899-21-000093 · wf-form4_163346563868452.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,155,063 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $48.85 to $49.81 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 10:53 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,892 | $54.92 | $598,188.64 |
DisclosureSEC source: 0001714899-21-000089 · wf-form4_163066639800542.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,158,367 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $54.57 to $55.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 10:53 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,441 | $54.27 | $403,823.07 |
DisclosureSEC source: 0001714899-21-000089 · wf-form4_163066639800542.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,169,259 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $53.57 to $54.56 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| August 19, 2021 Filed Aug 24, 2021 00:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 750 | $49.97 | $37,477.50 |
DisclosureSEC source: 0001714899-21-000085 · wf-form4_162976467767655.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,176,700 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.81 to $50.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| August 19, 2021 Filed Aug 24, 2021 00:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,626 | $49.38 | $80,291.88 |
DisclosureSEC source: 0001714899-21-000085 · wf-form4_162976467767655.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,177,450 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $48.81 to $49.80 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 5000 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 23:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,790 | $51.94 | $508,492.60 |
DisclosureSEC source: 0001714899-21-000080 · wf-form4_162811883181212.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,174,076 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $51.42 to $52.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 23:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,543 | $50.80 | $433,984.40 |
DisclosureSEC source: 0001714899-21-000080 · wf-form4_162811883181212.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,183,866 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $50.42 to $51.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,459 | $77.84 | $191,401.18 |
DisclosureSEC source: 0001209191-21-045422 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,192,409 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $77.67 to $78.25 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 12,844 | $77.35 | $993,470.56 |
DisclosureSEC source: 0001209191-21-045422 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,194,868 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $76.67 to $77.665 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,030 | $76.38 | $231,428.37 |
DisclosureSEC source: 0001209191-21-045422 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,207,712 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $75.67 to $76.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 354 | $63.50 | $22,479.00 |
DisclosureSEC source: 0001209191-21-037981 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,210,742 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,102 | $62.76 | $131,911.01 |
DisclosureSEC source: 0001209191-21-037981 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,211,096 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $62.50 to $63.055 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,750 | $62.09 | $170,747.50 |
DisclosureSEC source: 0001209191-21-037981 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,213,198 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $61.50 to $62.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 13,127 | $60.98 | $800,510.71 |
DisclosureSEC source: 0001209191-21-037981 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,215,948 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.48 to $61.46 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 851 | $59.92 | $50,989.37 |
DisclosureSEC source: 0001209191-21-030300 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,229,075 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $59.79 to $60.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,485 | $59.12 | $206,029.72 |
DisclosureSEC source: 0001209191-21-030300 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,229,926 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $58.765 to $59.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 13,997 | $58.45 | $818,082.66 |
DisclosureSEC source: 0001209191-21-030300 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,233,411 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.76 to $58.755 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,586 | $57.31 | $262,842.00 |
DisclosureSEC source: 0001209191-21-025115 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,247,408 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.038 to $58.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,516 | $56.88 | $484,356.02 |
DisclosureSEC source: 0001209191-21-025115 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,251,994 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.32 to $57.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,232 | $55.52 | $290,485.87 |
DisclosureSEC source: 0001209191-21-025115 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,260,510 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.245 to $56.235 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 09, 2021 Filed Apr 5, 2021 20:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025115 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,265,742 F1 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 68 | $70.92 | $4,822.83 |
DisclosureSEC source: 0001209191-21-016854 · doc4.xml · nonDerivative · entry 7 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,305,742 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.90 to $70.95 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 594 | $69.65 | $41,370.91 |
DisclosureSEC source: 0001209191-21-016854 · doc4.xml · nonDerivative · entry 6 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,305,810 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.28 to $69.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,625 | $68.46 | $111,245.88 |
DisclosureSEC source: 0001209191-21-016854 · doc4.xml · nonDerivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,306,404 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $68.155 to $69.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,339 | $67.69 | $226,016.91 |
DisclosureSEC source: 0001209191-21-016854 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,308,029 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.15 to $68.135 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,453 | $66.55 | $229,779.89 |
DisclosureSEC source: 0001209191-21-016854 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,311,368 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.15 to $67.105 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,885 | $65.63 | $386,209.01 |
DisclosureSEC source: 0001209191-21-016854 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,314,821 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $65.15 to $66.13 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,370 | $64.42 | $217,105.51 |
DisclosureSEC source: 0001209191-21-016854 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,320,706 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.12 to $65.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:40 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 960 | $71.47 | $68,610.24 |
DisclosureSEC source: 0001209191-21-011004 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,324,076 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.03 to $71.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 19,696 shares acquired pursuant to vesting of restricted stock units and issued directly to the Watts Family 2015 Trust dated July 7, 2015. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:40 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,513 | $70.17 | $597,374.24 |
DisclosureSEC source: 0001209191-21-011004 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,325,036 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.71 to $70.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 19,696 shares acquired pursuant to vesting of restricted stock units and issued directly to the Watts Family 2015 Trust dated July 7, 2015. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:40 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 811 | $75.07 | $60,883.39 |
DisclosureSEC source: 0001209191-21-009455 · doc4.xml · nonDerivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,313,853 F3 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $74.79 to $75.195 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:40 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,634 | $74.05 | $120,999.33 |
DisclosureSEC source: 0001209191-21-009455 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,314,664 F3 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $73.62 to $74.50 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:40 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,667 | $73.24 | $195,328.41 |
DisclosureSEC source: 0001209191-21-009455 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,316,298 F3 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $72.61 to $73.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:40 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 8,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009455 · doc4.xml · derivative · entry 7 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 8,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F8 · derivative.exercise_date: 25% of the restricted stock units vested on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F8 · derivative.expiration_date: 25% of the restricted stock units vested on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.